Founded in 2012, Ascendia offers a comprehensive suite of pre-formulation, formulation development, manufacturing, and stability services for parental, oral, and topical dosage forms. The Company also provides analytical method development and validation services for those dosage forms. The Company’s extensive formulation development expertise is supported by its technology platforms in nanoparticle, amorphous solid dispersion, and nano-emulsions. This enables them to solve complex solubility and bioavailability challenges for a wide variety of molecules with difficult properties. Coupled with a customer-centric culture that exudes the BEST consisting of Brilliant technology, Excellent service, Superior quality, and Trust, Ascendia’s team of colleagues and unique capabilities allow it to be nimble and collaborative; often earning them the coveted Partner of Choice status by its valued customers.
Ascendia’s CEO Dr.
View original content to download multimedia:http://www.prnewswire.com/news-releases/ascendia-pharmaceuticals-secures-growth-equity-investment-from-signet-healthcare-partners-301265086.html